Ribavirin: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Jamie Costa (talk | contribs) No edit summary |
Jamie Costa (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
== Overview == | == Overview == | ||
Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients. Since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b. (from “Gish” in general info) | |||
== Function == | == Function == | ||
== | == Disease == | ||
== | == Relevance == | ||
== Structural highlights == | |||
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes. | ||
Revision as of 02:39, 15 November 2016
==Your Heading Here (maybe something like 'Structure')== 0
| ||||||||||||
References
Proteopedia Page Contributors and Editors (what is this?)
Jamie Costa, Edmond R Atalla, Taylor H. Derby, Katherine Reynolds, Shannon Shaughnessy, Alexander Berchansky
